Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 30 2025
0mins
Source: Benzinga
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NDRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NDRA
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.000
Low
30.00
Averages
30.00
High
30.00
Current: 4.000
Low
30.00
Averages
30.00
High
30.00
About NDRA
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
Continue Reading
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
- Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
- Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
- Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
- Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
Continue Reading